Prediction of venous thromboembolism in cancer patients.

@article{Ay2010PredictionOV,
  title={Prediction of venous thromboembolism in cancer patients.},
  author={Cihan Ay and Daniela Dunkler and Christine Marosi and Alexandru Chiriac and Rainer Vormittag and Ralph Simanek and Peter Quehenberger and Christoph Zielinski and Ingrid Pabinger},
  journal={Blood},
  year={2010},
  volume={116 24},
  pages={
          5377-82
        },
  url={https://api.semanticscholar.org/CorpusID:206889357}
}
Clinical and standard laboratory parameters with addition of biomarkers enable prediction of VTE and allow identification of cancer patients at high or low risk of V TE.
View on PubMed
ashpublications.org
676 Citations
Highly Influential Citations
24
Background Citations
128
Methods Citations
78
Results Citations
12

Figures and Tables from this paper

676 Citations

Performance of Current Thromboembolism Risk Assessment Tools in Patients With Gastric Cancer and Validity After First Treatment

Posttreatment KRS appears as a valid tool to identify patients with GC at high risk of VTE after first cancer treatment, validated for VTE prediction in patient with cancer.

Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study

The prediction scores performed poorly in predicting venous thromboembolism in cancer patients, and the Vienna CATS and PROTECHT scores appear to discriminate better between low- and high-risk patients, but further improvements are needed before they can be considered for introduction into clinical practice.

A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.

The Clinical Risk Score, originally developed to predict the occurrence of VTE, is also predictive of early mortality and cancer progression during the first four cycles of outpatient chemotherapy, independent from other major prognostic factors including VTE itself.

Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study.

Development and validation of a clinical prediction model for cancer-associated venous thromboembolism in two independent prospective cohorts

An externally-validated clinical prediction model incorporating only one clinical factor (tumor site category) and one biomarker (D-Dimer) predicts the risk of VTE in ambulatory patients with solid cancers and considerably improves on previous models for predicting cancer-associated VTE.

The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer.

Predicting recurrent venous thromboembolism in cancer: is it possible?

Clinical prediction scores for venous thromboembolism in patients with a hematological malignancy

An overview of the performance and potential clinical utility of the currently available risk scores for cancer-associated VTE in patients with a hematological malignancy is provided.

Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma

The study indicates that the pre-chemotherapy MPV value, while of no use as an overall prognosis predictor, may still represent a useful prognostic marker for a significant VTE risk especially when incorporated into VTE-risk assessment models.

Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study.

Investigation of thrombin generation, a key process in hemostasis, as predictor of cancer-associated venous thromboembolism found it to help identify patients with cancer at high risk of VTE.
...

47 References

Assessing risk of venous thromboembolism in the patient with cancer.

Identifying patients with cancer who are most at risk for VTE is essential to better target thromboprophylaxis, with the eventual goal of reducing the burden as well as the consequences of VTE for patients withcancer.

Development and validation of a predictive model for chemotherapy-associated thrombosis.

A simple model for predicting chemotherapy-associated venous thromboembolism using baseline clinical and laboratory variables can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis.

Predicting recurrences or major bleeding in cancer patients with venous thromboembolism

Cancer patients with acute venous thromboembolism (VTE) have an increased incidence of recurrences and bleeding complications while on anticoagulant therapy, and which cancer patients are at a higher risk for recurrent pulmonary embolism, deep vein thrombosis (DVT) or major bleeding is identified.

Risk factors for venous thromboembolic events in cancer patients.

In cancer patients the risk of VTE steadily increases with the number of risk factors, and identification of patients at high risk is possible.

Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.

The incidence of VTE among colorectal cancer patients was highest in the first 6 months after diagnosis and decreased rapidly thereafter, suggesting that, in these patients, VTE may reflect the presence of a biologically more aggressive cancer.

Circulating P-selectin and the risk of recurrent venous thromboembolism

It is concluded that high circulating P-selectin is a risk factor of recurrent VTE, and adjusted risk of recurrence was increased among patients with P- selectin levels exceeding the 75th percentile.

Identifying cancer patients at risk for venous thromboembolism.

Risk stratification of cancer patients will allow clinicians to identify those patients at highest risk for VTE, who may derive the most benefit from thromboprophylaxis.

D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.

High D-dimer and F 1 + 2 levels independently predict occurrence of VTE in patients with cancer.

D-dimer before chemotherapy might predict venous thromboembolism

Baseline D-dimer values in cancer patients scheduled for chemotherapy might be used to select those at low risk of VTE, most likely to be safe without prophylaxis, to establish the best benefit/risk-of-bleeding ratio.

High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

High platelet count is a clinically important, independent risk predictor for venous thromboembolism in cancer patients and was not found to be associated with TPO levels.